Open Nav

Please submit your session questions in advance at

Kevin Outterson

Professor and N. Neal Pike Scholar in Health and Disability Law;Executive Director & Principal Investigator

Boston University;CARB-X
  • Industry:Industry is private

Professor Outterson teaches health care law at Boston University, where he co-directs the Health Law Program. He serves as the Executive Director and Principal Investigator for CARB-X, a $540M international public-private partnership to accelerate global antibacterial innovation. Key partners in CARB-X include the US Government (BARDA & NIAID), the Wellcome Trust, the UK Government (GAMRIF, DHSC), the German Federal Ministry of Education and Research, and the Bill & Melinda Gates Foundation.

His research work focuses on the law and economics of antimicrobial resistance. Professor Outterson was a founding member of the Antimicrobial Resistance Working Group at the CDC. He was a senior consultant on the Eastern Research Group study on antibiotic markets for FDA/HHS. Starting in October 2014, he joined DRIVE-AB, a three-year €9 million project on antibiotic business models sponsored by the European Union’s Innovative Medicines Initiative. Professor Outterson also serves on the Advisory Panel for the Longitude Prize for an inexpensive rapid point-of-care antibiotic diagnostic. Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before Congress, Parliamentary working groups, WHO, and several state legislatures.

This speaker's sessions: